Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRME Stock Forecast 2026-2027
$3.06
Current Price
$552.69M
Market Cap
Buy 9
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to PRME Price Targets
+259.5%
To High Target of $11.00
+96.1%
To Median Target of $6.00
+38.9%
To Low Target of $4.25
PRME Price Momentum
-13.8%
1 Week Change
-10.3%
1 Month Change
+81.1%
1 Year Change
-11.8%
Year-to-Date Change
-55.9%
From 52W High of $6.94
+134.5%
From 52W Low of $1.31
📊 TOP ANALYST CALLS
Did PRME Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prime Medicine is one of their latest high-conviction picks.
Latest PRME Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PRME has a bullish consensus with a median price target of $6.00 (ranging from $4.25 to $11.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $3.06, the median forecast implies a 96.1% upside. This outlook is supported by 9 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kostas Biliouris at Oppenheimer, projecting a 259.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRME Analyst Ratings
9
Buy
4
Hold
0
Sell
PRME Price Target Range
Low
$4.25
Average
$6.00
High
$11.00
Current: $3.06
Latest PRME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | Oppenheimer | Kostas Biliouris | Outperform | Initiates | $11.00 |
| Dec 23, 2025 | LifeSci Capital | Outperform | Initiates | $N/A | |
| Nov 11, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Nov 10, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 12, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Aug 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 27, 2025 | Citigroup | Neutral | Downgrade | $N/A | |
| May 20, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| May 20, 2025 | JP Morgan | Neutral | Downgrade | $N/A | |
| May 20, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| May 19, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 20, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 4, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Mar 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 3, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 10, 2024 | JMP Securities | Market Outperform | Initiates | $N/A | |
| Dec 3, 2024 | Guggenheim | Buy | Reiterates | $N/A | |
| Oct 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 2, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
Prime Medicine Inc. (PRME) Competitors
The following stocks are similar to Prime Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prime Medicine Inc. (PRME) Financial Data
Prime Medicine Inc. has a market capitalization of $552.69M with a P/E ratio of -2.3x. The company generates $4.03M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -41.1% quarter-over-quarter, while maintaining an operating margin of -5,917.5% and return on equity of -216.1%.
Valuation Metrics
Market Cap
$552.69M
Enterprise Value
$531.70M
P/E Ratio
-2.3x
PEG Ratio
0.1x
Price/Sales
137.0x
Growth & Margins
Revenue Growth (YoY)
-41.1%
Gross Margin
N/A
Operating Margin
-5,917.5%
Net Margin
0.0%
EPS Growth
-41.1%
Financial Health
Cash/Price Ratio
+24.5%
Current Ratio
3.8x
Debt/Equity
149.3x
ROE
-216.1%
ROA
-41.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prime Medicine Inc. (PRME) Business Model
About Prime Medicine Inc.
What They Do
Develops one-time curative genetic therapies.
Business Model
The company utilizes its proprietary Prime Editing platform to create precise and efficient gene editing therapies targeting specific genetic disorders. It generates revenue through partnerships, such as its collaboration with Bristol Myers Squibb, and by advancing a diverse pipeline of treatments for various conditions, including Wilson's Disease and cystic fibrosis.
Additional Information
Prime Medicine Inc. is headquartered in Cambridge, Massachusetts, and focuses on innovative delivery methods like liver-targeted lipid nanoparticles. The company aims to address both rare genetic disorders and broader medical needs, leveraging its advanced gene editing technology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
146
CEO
Dr. Allan Reine M.D.
Country
United States
IPO Year
2022
Website
primemedicine.comPrime Medicine Inc. (PRME) Latest News & Analysis
Latest News
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) announced the appointment of Dr. Allan Reine as part of its focus on developing innovative one-time curative genetic therapies.
Why It Matters
Prime Medicine's announcement could signal advancements in gene therapy, potentially boosting stock value and attracting interest from investors in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) announced the appointment of Dr. Allan Reine, emphasizing its focus on developing innovative one-time genetic therapies.
Why It Matters
Prime Medicine's announcement could signal advancements in genetic therapies, potentially affecting stock performance and market sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
30 days ago
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) reported Q1 2026 financial results and a business update on May 7, 2026, focusing on its innovative genetic therapies.
Why It Matters
Prime Medicine's quarterly financial results and business update indicate its progress in developing innovative genetic therapies, impacting its market position and potential for future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prime Medicine, Inc. (PRME) reported a quarterly loss of $0.28 per share, worse than the expected loss of $0.24, but an improvement from a loss of $0.40 per share a year ago.
Why It Matters
PRME's larger-than-expected quarterly loss signals potential operational challenges, impacting investor sentiment and stock valuation. However, the reduced loss compared to last year may indicate improving performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) has appointed Svetlana Makhni as Chief Financial Officer, enhancing its leadership in developing one-time curative genetic therapies.
Why It Matters
The appointment of Svetlana Makhni as CFO could signal a strategic shift for Prime Medicine, potentially impacting financial management and investor confidence in its growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
3 months ago
Quick Summary
Prime Medicine, Inc. (PRME) presented at the TD Cowen 46th Annual Health Care Conference, highlighting updates and developments in their business strategy and pipeline.
Why It Matters
Prime Medicine's presentation at a major healthcare conference signals potential developments or breakthroughs, impacting investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PRME Stock
What is Prime Medicine Inc.'s (PRME) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Prime Medicine Inc. (PRME) has a median price target of $6.00. The highest price target is $11.00 and the lowest is $4.25.
Is PRME stock a good investment in 2026?
According to current analyst ratings, PRME has 9 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRME stock?
Wall Street analysts predict PRME stock could reach $6.00 in the next 12 months. This represents a 96.1% increase from the current price of $3.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prime Medicine Inc.'s business model?
The company utilizes its proprietary Prime Editing platform to create precise and efficient gene editing therapies targeting specific genetic disorders. It generates revenue through partnerships, such as its collaboration with Bristol Myers Squibb, and by advancing a diverse pipeline of treatments for various conditions, including Wilson's Disease and cystic fibrosis.
What is the highest forecasted price for PRME Prime Medicine Inc.?
The highest price target for PRME is $11.00 from Kostas Biliouris at Oppenheimer, which represents a 259.5% increase from the current price of $3.06.
What is the lowest forecasted price for PRME Prime Medicine Inc.?
The lowest price target for PRME is $4.25 from at , which represents a 38.9% increase from the current price of $3.06.
What is the overall PRME consensus from analysts for Prime Medicine Inc.?
The overall analyst consensus for PRME is bullish. Out of 4 Wall Street analysts, 9 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are PRME stock price projections?
Stock price projections, including those for Prime Medicine Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 10:21 AM UTC